ProPhase Labs Files 8-K on Shareholder Votes & Financials

Ticker: PRPH · Form: 8-K · Filed: Nov 26, 2025 · CIK: 868278

Prophase Labs, INC. 8-K Filing Summary
FieldDetail
CompanyProphase Labs, INC. (PRPH)
Form Type8-K
Filed DateNov 26, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0005
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, financial-reporting

Related Tickers: PRPH

TL;DR

ProPhase Labs (PRPH) filed an 8-K on Nov 24, 2025, covering shareholder votes and financials.

AI Summary

ProPhase Labs, Inc. filed an 8-K on November 26, 2025, reporting on matters submitted to a vote of security holders and financial statements. The earliest event reported was on November 24, 2025. The company, formerly known as QUIGLEY CORP, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides updates on important corporate actions and financial reporting, which can influence investor decisions regarding ProPhase Labs, Inc.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating immediate operational or financial distress.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What is the primary business of ProPhase Labs, Inc.?

ProPhase Labs, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.

When was ProPhase Labs, Inc. formerly known as?

ProPhase Labs, Inc. was formerly known as QUIGLEY CORP, with a name change date of March 28, 1993.

What is the principal executive office address of ProPhase Labs, Inc.?

The principal executive offices are located at 626 RXR Plaza, 6th Floor, Uniondale, New York, 11556.

What is the telephone number for ProPhase Labs, Inc.?

The registrant's telephone number, including area code, is (516) 903-0763.

Filing Stats: 671 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-11-26 14:15:29

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc. By: /s/ Ted Karkus Ted Karkus Chairman of the Board and Chief Executive Officer Date: November 26, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing